| Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides M Kramski, RJ Center, AK Wheatley, JC Jacobson, MR Alexander, ... Antimicrobial agents and chemotherapy 56 (8), 4310-4319, 2012 | 50 | 2012 |
| Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells LR Gray, H On, E Roberts, HK Lu, MA Moso, JA Raison, C Papaioannou, ... Journal of neurovirology 22, 455-463, 2016 | 34 | 2016 |
| HIV latency reversing agents act through Tat post translational modifications G Khoury, TM Mota, S Li, C Tumpach, MY Lee, J Jacobson, L Harty, ... Retrovirology 15, 1-17, 2018 | 27 | 2018 |
| Identification of 5-substituted 2-acylaminothiazoles that activate Tat-mediated transcription in HIV-1 latency models W Nguyen, J Jacobson, KE Jarman, H Jousset Sabroux, L Harty, ... Journal of Medicinal Chemistry 62 (10), 5148-5175, 2019 | 13 | 2019 |
| HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal MA Moso, JL Anderson, S Adikari, LR Gray, G Khoury, JJ Chang, ... AIDS 33 (2), 199-209, 2019 | 7 | 2019 |
| Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents W Nguyen, J Jacobson, KE Jarman, TR Blackmore, HJ Sabroux, ... European Journal of Medicinal Chemistry 195, 112254, 2020 | 2 | 2020 |
| HIV-specific latency reversing therapies that exploit novel pathways for suboptimal Tat protein expression D Purcell, J Jacobson, L Harty, K Jarman, K Lackovic, G Khoury, T Mota, ... Journal of the International Aids Society 18 (10.7448), 2015 | 1 | 2015 |
| Activators of hiv latency B Sleebs, DFJ Purcell, J Jacobson, S Lewin, W Nguyen US Patent App. 16/310,646, 2019 | | 2019 |
| 4 New HIV specific latency reversing agents with novel targets that synergise with HIV Tat and the bromodomain inhibitor, JQ1 to reactivate HIV from primary cells. J Jacobson, B Sleebs, K Jarman, W Nguyen, T Mota, L Harty, G Khoury, ... | | 2017 |
| A novel assay to evaluate the response of patient-derived virus to latency reversing agents ex vivo H Lu, M Moso, L Gray, K Cheong, T Mota, J Jacobson, A Ellett, WJ Cheng, ... Infection 2, 0, 2016 | | 2016 |
| Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal SDF TM Mota, G Khoury, JC Jacobson, HK Lu, F Wightman, RM Van der Sluis, ... JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 19, 2016 | | 2016 |
| 23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal TM Mota, G Khoury, JC Jacobson, HK Lu, F Wightman, JL Anderson, ... | | 2016 |
| 37 Novel pathways of Tat expression identify new targets for reactivation of latent HIV-1 M Lee, J Jacobson, M Olshansky, T Mota, S Lewin, G Khoury, S Sonza, ... | | 2016 |
| HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu (" Our Love … A Ericsen, M Lauck, M Mohns, S Dinapoli, J Mutschler, J Greene, ... | | 2016 |
| 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19â 22 July 2015, Vancouver, Canada KM Pate, C Pohlmeyer, V Walker‐Sperling, J Foote, K Najarro, C Cryer, ... International AIDS Society, 2015 | | 2015 |
